Product Description
JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody, is used in patients with advanced cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05296772)
Mechanisms of Action: IL21 Antagonist,Albumin Antagonist
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Anwita Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for JS-014](https://pryzm-maps.s3.us-west-2.amazonaws.com/799current_maps.png)
Countries in Clinic: Taiwan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AWT-EXK21-001 | P1 |
Recruiting |
Lymphoma |
2024-06-01 |
44% |